Literature DB >> 20587513

Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells.

Yosuke Harada1, Mitsugu Kanehira, Yoshiko Fujisawa, Ryo Takata, Taro Shuin, Tsuneharu Miki, Tomoaki Fujioka, Yusuke Nakamura, Toyomasa Katagiri.   

Abstract

Bladder cancer is the second most common genitourinary cancer worldwide, yet its oncogenic origins remain poorly understood. The cancer-testis antigen DEPDC1 was shown recently to contribute to bladder cancer oncogenesis. In this study, we examined the biological functions of DEPDC1 and defined a potential therapeutic strategy to target this molecule. Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. Inhibiting this interaction with a cell-permeable peptide corresponding to the ZNF224-interacting domain in DEPDC1 induced apoptosis of bladder cancer cells in vitro and in vivo. By inhibiting DEPDC1-ZNF224 complex formation, this peptide triggered transcriptional activation of A20, a potent inhibitor of the NF-kappaB signaling pathway. Our findings indicate that the DEPDC1-ZNF224 complex is likely to play a critical role in bladder carcinogenesis. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587513     DOI: 10.1158/0008-5472.CAN-10-0255

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro.

Authors:  Li Sun; Hong-xiang Wang; Xiao-jian Zhu; Pin-hui Wu; Wei-qun Chen; Ping Zou; Qiu-bai Li; Zhi-chao Chen
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

2.  A time-series analysis of altered histone H3 acetylation and gene expression during the course of MMAIII-induced malignant transformation of urinary bladder cells.

Authors:  Jinqiu Zhu; Jie Wang; Xushen Chen; Maria Tsompana; Daniel Gaile; Michael Buck; Xuefeng Ren
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

3.  Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.

Authors:  Daiki Miki; Hidenori Ochi; C Nelson Hayes; Hiromi Abe; Tadahiko Yoshima; Hiroshi Aikata; Kenji Ikeda; Hiromitsu Kumada; Joji Toyota; Takashi Morizono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Nakamura; Naoyuki Kamatani; Kazuaki Chayama
Journal:  Nat Genet       Date:  2011-07-03       Impact factor: 38.330

Review 4.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

5.  MED28 increases the colony-forming ability of breast cancer cells by stabilizing the ZNF224 protein upon DNA damage.

Authors:  Jin Gu Cho; Key-Hwan Lim; Sang Gyu Park
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

6.  Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells.

Authors:  Ryogo Kikuchi; Oltea Sampetrean; Hideyuki Saya; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

7.  Human genetic variation and the risk of hepatocellular carcinoma development.

Authors:  Sayeh Ezzikouri; Soumaya Benjelloun; Pascal Pineau
Journal:  Hepatol Int       Date:  2013-08-02       Impact factor: 6.047

8.  Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro.

Authors:  Miki Tsuruta; Shohei Ueda; Poh Yin Yew; Isao Fukuda; Sachiko Yoshimura; Hiroyuki Kishi; Hiroshi Hamana; Masatoshi Hirayama; Junji Yatsuda; Atsushi Irie; Satoru Senju; Eiji Yuba; Tomomi Kamba; Masatoshi Eto; Hideki Nakayama; Yasuharu Nishimura
Journal:  Oncoimmunology       Date:  2018-01-05       Impact factor: 8.110

9.  UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Authors:  Emily S Reardon; Vivek Shukla; Sichuan Xi; Sudheer K Gara; Yi Liu; David Straughan; Mary Zhang; Julie A Hong; Eden C Payabyab; Anju Kumari; William G Richards; Assunta De Rienzo; Raffit Hassan; Markku Miettinen; Liqiang Xi; Mark Raffeld; Lisa T Uechi; Xinmin Li; Ruihong Wang; Haobin Chen; Chuong D Hoang; Raphael Bueno; David S Schrump
Journal:  J Thorac Oncol       Date:  2020-09-11       Impact factor: 15.609

10.  In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers.

Authors:  Jongchan Kim
Journal:  World J Surg Oncol       Date:  2021-06-25       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.